ConductScience.org, home

Library / Genes

AKT2: AKT serine/threonine kinase 2

1 protein, 148 patents, 14 drugs, 174 trials, 4,505 NIH grants and 8,117 papers.

Gene 7

Its symbol and name are HGNC's, unless HGNC and NCBI Gene contradict each other.

FieldValueSource
SymbolAKT2HGNC
NameAKT serine/threonine kinase 2HGNC
NCBI Gene ID208NCBI Gene
HGNC IDHGNC:392HGNC
EnsemblENSG00000105221NCBI Gene
AliasesHIHGHH, PKBB, PKBBETA, PKBβ, PRKBB, RAC-BETANCBI Gene
Typeprotein-codingNCBI Gene

Proteins 1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated inSource
P31751RAC-beta serine/threonine-protein kinase48119Ensembl, GeneID, HGNCUniProt

Patents 148

Patents whose sequence listing holds the protein exactly: the same sequence, by SHA-256, length and CRC-64. A sequence a patent lists is not always one it claims.

PublicationPublishedSEQ ID NOProteinSource
EP 4650780 A22025-11-1910887P31751Espacenet
JP 2025517970 A2025-06-1210887P31751Espacenet
EP 4484957 A12025-01-018P31751Espacenet
JP 2024123008 A2024-09-108937P31751Espacenet
JP 2024123008 A2024-09-108941P31751Espacenet
US 11892452 B22024-02-0620P31751Espacenet
JP 2023123507 A2023-09-0540P31751Espacenet
WO 2023162878 A2023-08-318P31751Espacenet
US 11708396 B22023-07-251380P31751Espacenet
US 11708396 B22023-07-251386P31751Espacenet

Drugs 14

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
AFURESERTIBCHEMBL2219422Serine/threonine-protein kinase AKT inhibitorINHIBITORChEMBL
BAY-1125976CHEMBL4751394Serine/threonine-protein kinase AKT2 inhibitorINHIBITORChEMBL
CAPIVASERTIBCHEMBL2325741Serine/threonine-protein kinase AKT inhibitorINHIBITORChEMBL
GSK-690693CHEMBL494089Serine/threonine-protein kinase AKT inhibitorINHIBITORChEMBL
IPATASERTIBCHEMBL2177390Serine/threonine-protein kinase AKT inhibitorINHIBITORChEMBL
LY-2780301CHEMBL3545134Serine/threonine-protein kinase AKT inhibitorINHIBITORChEMBL
MIRANSERTIBCHEMBL4297188Serine/threonine-protein kinase AKT inhibitorINHIBITORChEMBL
MK-2201CHEMBL3545000Serine/threonine-protein kinase AKT inhibitorINHIBITORChEMBL
MK-2206CHEMBL1079175Serine/threonine-protein kinase AKT inhibitorINHIBITORChEMBL
PIFUSERTIBCHEMBL4297329Serine/threonine-protein kinase AKT negative allosteric modulatorNEGATIVE ALLOSTERIC MODULATORChEMBL

Trials 174

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT07486648CAPIVASERTIBPHASE1/PHASE2ClinicalTrials.gov
NCT07426822CAPIVASERTIBPHASE2ClinicalTrials.gov
NCT07294677CAPIVASERTIBPHASE1/PHASE2ClinicalTrials.gov
NCT07281833CAPIVASERTIBPHASE3ClinicalTrials.gov
NCT07175415CAPIVASERTIBPHASE1/PHASE2ClinicalTrials.gov
NCT06837792CAPIVASERTIBPHASE2ClinicalTrials.gov
NCT06764186CAPIVASERTIBPHASE3ClinicalTrials.gov
NCT06635447CAPIVASERTIBPHASE3ClinicalTrials.gov
NCT06613516CAPIVASERTIBPHASE2ClinicalTrials.gov
NCT06607757CAPIVASERTIBPHASE2ClinicalTrials.gov

NIH grants 4505

NIH projects whose papers are about the gene, through NIH's grant-paper links.

ProjectTitleIts papers about the geneNewest fiscal yearSource
P30CA016672Cancer Center Support Grant1162,025NIH's project files
P30CA008748Cancer Center Support Grant672,025NIH's project files
P30CA006927Comprehensive Cancer Center Program at Fox Chase342,025NIH's project files
P30CA016058Cancer Center Support Grant182,025NIH's project files
P30CA076292Moffitt Cancer Center Support Grant172,025NIH's project files
R01CA090764PI3K/PTEN/Akt signaling and the genesis of cancer172,025NIH's project files
P30CA006973Regional Oncology Research Center162,025NIH's project files
P30DK020572Michigan Diabetes Research Center (MDRC)162,025NIH's project files
P30CA068485Cancer Center Support Grant152,025NIH's project files
P01CA120964Molecular Pathogenesis of the Hamartoma Syndromes132,025NIH's project files

Papers 8117

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

PMIDFound bySource
42816254PubTator, text miningPubMed
42808171PubTator, text miningPubMed
42792909PubTator, text miningPubMed
42792848PubTator, text miningPubMed
42789557PubTator, text miningPubMed
42758762PubTator, text miningPubMed
42736652PubTator, text miningPubMed
42721895PubTator, text miningPubMed
42704227PubTator, text miningPubMed
42671015PubTator, text miningPubMed

The same record as JSON

Release gene-search-2026-11-11-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ChEMBL, through Open Targets: CC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

EMBL-EBI's patent proteins: EMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use

GenBank's patent files: GenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/

HGNC: CC0: https://www.genenames.org/about/license/

NCBI Gene: None named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/

NIH's project files and grant-paper links: Public domain (NIH RePORTER)

Open Targets: CC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

PubTator 3: Public domain

UniProt: CC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license